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significant aspects of selected presentations. Addi-
tional information is available on a DVD, which in-
cludes the audio and slides of consenting speakers
and can be obtained by sending a request, including
mailing address, to SymposiumDVD@cordbloodforu-
m.org.SESSION I. CLINICAL RESULTS IN UMBLICAL
CORD BLOOD TRANSPLANTATION
John E. Wagner, MD, University of Minnesota,
reviewed progress in UCBT. There has been a substan-
tial decrease in treatment-related mortality (TRM)
after UCBT, from 54% in 1994-1999, to 34% in
2000-2002 and 27% in 2003-2006. The reasons for
this include a better understanding of requirements
for cell dose, HLA matching, and their interaction,
as well as improved conditioning regimens. In addi-
tion, there have been improvements in supportive
care and in CB collection and quality. Another impor-
tant factor is the move toward earlier referrals to min-
imize UCBT in patients with late-stage disease.
A significant body of data points to an interaction
between HLA matching and cell dose, in that a high
cell dose can overcome to some extent the negative
effect of HLA mismatching. The minimum cell dose
is now generally set at 2.5 107 total nucleated cells
(TNCs)/kg. With increased HLA mismatching,
a higher cell dose should be used. Suggested cell doses
(in TNC/kg) are 2.5-3.0 for a 6/6 HLA match, 4.0 for
a 5/6 HLA match, and 5.0 for a 4/6 HLA match. At the
University of Minnesota, a double UCBT is per-
formed if these cell doses cannot be achieved with
a single CB unit.
Adults have greater difficulty finding adequate
CB units for transplantation because of the limited
number of cryopreserved units with a large cell
dose in CB banks. Recent data comparing UCBT
with the ‘‘gold standard’’ of allele-matched bone
marrow transplantation (BMT) indicates that treat-
ment failure (death or relapse) is now comparable
(relative risk of treatment failure in BMT vs mis-
matched UCBT5 0.82 [P5 .13]; in peripheral blood
stem cell transplantation [PBSCT] vs mismatched
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room for improvement regardless of the stem cell
source.
The use of double UCBT is one way to extend the
option of UCBT to adults who do not have a single CB
unit with an adequate cell dose. Data from the Univer-
sity of Minnesota indicate that in 105 patients treated
with myeloablative (MA) conditioning, the median
time to engraftment was 23 days and the overall neu-
trophil engraftment rate was 89%. Using a nonmyeloa-
blative (NMA) regimen in 188 patients, the median
time to engraftment was 12 days and the neutrophil en-
graftment rate was 95%. In both instances, the overall
survival (OS) and disease-free survival (DFS) were
quite good. Also, relapse may be reduced with the
use of double UCBT.
Vanderson Rocha, MD, PhD, Hoˆpital Saint-Louis,
Paris, France, discussed Eurocord data. About 14,000
unrelated UCBTs were performed between 1997 and
2006 worldwide, and about 2000 to 3000 new UCBTs
are performed annually. Eurocord has 3822 registered
cases, including 3019 single UCBTs (81 second
UCBTs), 572 double UCBTs (27 second UCBTs),
56 UCBTs using an expanded unit, 57 with CB 1
haplo, 51 with CB1 BM, and 70 with intrabone
UCBTs. In children with malignancies (n5 1099),
OS was 46% in early-phase disease, 37% in intermedi-
ate-phase disease, and 30% in advanced disease.
There has been a learning curve in UCBT, as
indicated by the trend in OS in adults with malignant
disease over the years: 23% in 1994-1998, 31% in
1999-2000, 36% in 2001-2003, and 38% in 2004-
2008. The major factors affecting outcomes are
increasing cell dose (double UCBT), improved donor
choice, decreasing HLA disparities (because of in-
creasing inventory of CB banks), better indications,
increased center experience, better infection manage-
ment, and modifications of GVHD prophylaxis and
conditioning regimens. Before 2000, 55% of patients
who underwent transplantation had advanced disease,
compared with only 38% between 2005 and 2008. In
adults with malignancies (n5 769) receiving single-
unit UCBT, DFS was 24% in those with advanced
disease, 33% in those with intermediate disease, and
40% in those with early-phase disease.
Intrabone injection of single CB units resulted
in an increased incidence of platelet recovery and
decreased grade III-IV acute GVHD (aGVHD), but
no statistically significant improvement in neutrophil
recovery, relapse, nonrelapse mortality (NRM), or OS.
The use of double UCBT and reduced-intensity
conditioning (RIC) is increasing steadily. Between
2003 and 2007 MA. Of the 74 patients, 51% had acute
myelocytic leukemia (AML), 49% had acute lympho-
cytic leukemia. While most were in complete remis-
sion (CR, 34% CR1 and 50% CR2), 16% were in an
advanced phase of the disease. The median time toneutrophil recovery was 26 days; aGVHD at day 100
was 45% (grade III, 7%; grade IV, 3%). OS at about
1 year was 47% for patients who underwent transplan-
tation while in remission (n5 60) and 18% in those
who underwent transplantation with advanced disease
(n5 14).
Outcome data are available on 155 UCBTs using
RIC (96 single UCBTs and 59 double UCBTs). The
conditioning regimen utilized cyclophosphamide
(Cy), fludarabine (Flu), and total body irradiation
(TBI). Median follow-up was 18 months, median pa-
tient age was 46.7 years, and 35% of the patients had re-
ceived a previous autologous transplant. Neutrophil
engraftment was 94% with 0 or 1 HLA disparity and
73% with 2 or more HLA disparities. The relapse
rate was 36% for single UCBTs and 24% for double
UCBTs (P5 .13). DFS was 56% for double UCBTs
and 49% for single UCBTs (P5 .53); DFS was 70%
with 0 or 1 HLA disparity and 42% with 2 or more
HLA disparities (P5 .002).
In conclusion, outcomes after UCBT in children
and especially in adults have improved over the last
4 years; cell dose is the major factor for outcome in
children and adults after MAC or RIC; delayed
engraftment and early increased mortality are associ-
ated with higher number of HLA disparities; there is
a need to increase the donor pool; other modifiable
factors, such as conditioning regimen and GVHD pro-
phylaxis, can improve outcomes; and encouraging
results have been obtained with double UCBT after
RIC or MAC, but follow-up is still short.
Mary Eapen, MD, The Medical College of Wisconsin,
discussed the effect of stem cell sources on leukemia-
free survival (LFS) after allogeneic transplantation
for ALL and AML in children. A total of 116 BMTs
were compared with 503 UCBTs performed in the
United States between 1995 and 2003. The median
follow-up of survivors was 5 years for BMT and
4 years for UCBT. All of the BMTs were HLA-
matched at the allele level, whereas for the UCBTs
(antigen-level matching), 7% were HLA-matched,
40% had 1 antigen mismatch (MM), and 53% had 2
antigen MMs. Results indicated that relative to
matched BMT, matched and 1-antigen MM high–
cell dose UCBTs had a lower rate of GVHD and
similar rates of TRM, relapse, and LFS. Two-antigen
MM UCBTs had lower GVHD, higher rates of
early TRM, lower rates of relapse and similar rates
of LFS.
In conclusion, HLA-mismatched UCBT with an
adequate cell dose is an acceptable alternative when
an 8/8 unrelated adult donor is not available or when
treatment is urgent, as is often the case in patients
with acute leukemia. In addition, an analysis of match-
ing at the HLA-C locus indicated that the data do not
support considering such matching outside the context
of a research protocol.
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cusseddouble UCBTandrelapse.Celldosehas a critical
impact on the outcome of UCBT, affecting the speed of
neutrophil recovery, risk of TRM, and survival. In addi-
tion, it magnifies the influence of HLA disparity and has
a significant effect on access to transplantation and the
probability of engraftment. Thus, increasing cell dose
may result in improved engraftment and survival.
Experience with double UCBT has indicated that
sustained donor engraftment is derived from one of
the units after day 1100, even though dual engraft-
ment can be demonstrated in 33% of cases at day
128. Outcome data indicate that compared with single
UCBT, double UCBT promotes engraftment. The
risk of grade II-IV aGVHD is higher after double
UCBT, but there is no difference in grade III-IV
aGVHD; the incidence of chronic GVHD (cGVHD)
also is similar. There is a reduced risk of relapse after
MAC conditioning for patients in CR1 or CR2.
More recently, investigators studied the impact of
absolute lymphocyte count (ALC) recovery on out-
come. Previous studies have indicated an association
between rapid ALC recovery and improved DFS fol-
lowing autologous and allogeneic PBSCT and BMT
in patients with ALL/AML, Hodgkin disease (HD)/
non-Hodgkin lymphoma (NHL), and multiple mye-
loma. However, no study has reported an association
between ALC and UCBT outcome. In an analysis of
outcomes of 80 patients, ALC .200 at day 128 after
UCBT was associated with reduced TRM, improved
DFS and OS, and a lower incidence of early bacterial
and viral infections. ALC was not associated with
age, weight, graft content, or number of CB units used
(single vs double UCBT), GVHD, relapse, or early
fungal or late infections.SESSION II. CONDITIONING REGIMENS IN
CORD BLOOD TRANSPLANTATION
Juliet Barker, MD, Memorial Sloan-Kettering Cancer
Center, presented a review of conditioning regimens in
UCBT. Because the use of double UCBT coincided
with changes in conditioning regimen, it is not yet pos-
sible to distinguish the relative contribution of double
UCBT versus the conditioning regimen in the various
transplantation outcomes. The contribution of double
UCBT is being studied in a Blood and Marrow Trans-
plant Clinical Trials Network (BMT-CTN) single-
versus-double randomized trial in patients up to the
age of 21 years. The Memorial Sloan-Kettering Cancer
Center approach to UCBT preparative regimens is that
all patients receive fludarabine (Flu) and none receive
antithymocyte globulin (ATG), steroids, or methotrex-
ate (MTX). Regimens vary depending on the disease
and patient age, as follows: high- dose (age# 50 years),
acute leukemia/myelodysplastic syndrome (MDS)/
high-grade NHL; RIC (age\70 years), AML/ALL/MDS or HD not in CR; NMA (age\70 years), HD
in CR/indolent NHL/chronic lymphocytic leukemia
(CLL). The NMA but immunosuppressive regimen
consists of Cy 50 mg/Flu/TBI 200 cGy. An RIC, but
still ablative, regimen is Cy 50 mg/Thio/Flu/TBI 400
cGy or melphalan (Mel)140 mg/Flu 150 mg. A high-in-
tensity ablative regimen is Cy 120 mg/Flu/TBI 1375
cGy. In conclusion, highly immunosuppressive regi-
mens yield a high incidence of sustained engraftment.
Plans are being made to look beyond engraftment to
further improve outcomes. The main challenges are
toxicity, GVHD, and relapse. RIC/NMA transplanta-
tion can substantially extend the access to transplanta-
tion. ATG is associated with infectious complications
and thus is not ideal. However, what is optimal immune
suppression? Is there a need to investigate new immu-
nosuppressants? Cyclosporine A (CsA)/mycopheno-
late mofetil (MMF) may not provide adequate
immunosuppression.
Claudio Brunstein, MD, University of Minnesota, pre-
sented an update of the University of Minnesota’s
experience in MA and NMA conditioning regimens.
Early experience in a mostly pediatric population indi-
cates that UCBT appears to be a valuable alternative to
unrelated adult donor transplantation. Also, the
CD341 cell dose, closely correlated to the TNC
dose, affected both engraftment and survival. How-
ever, the inability to find CB units with an adequate
cell dose limited the applicability of this approach in
larger adolescents and adults. Furthermore, for many
adults, even if a sufficiently large CB unit was available,
the patient often was too old or had a comorbidity that
precluded myeloablation.
To extend the use of hematopoietic cell transplan-
tation (HCT) to adults and older patients, the feasibil-
ity of double UCBT with MAC and non-MAC
regimens was investigated. Single UCBT was consid-
ered adequate in cases of a 6/6 HLA match with
a TNC$ 3.0 107/kg or in cases of a 5/6 HLA match
with a TNC$ 4.0 107/kg. When only 4/6 matched
units were available, a double UCBT was performed.
For double UCBT, a maximum of 2 HLA mismatches
(HLA-A and –B, antigen level; HLA-DRB1, allele
level) were allowed between the units and the patient
and also between the 2 units. The MAC regimen was
modified from previous regimens to include Flu and
MMF rather than ATG and methylprednisolone in
the conditioning and posttransplantation regimen.
An analysis of outcomes was performed in 194
patients with AML, ALL, CML, or MDS who under-
went transplantation between 1995 and 2006. The
data indicate that (1) engraftment even in adults was
prompt and graft failure was uncommon (10%); (2)
the relapse rate, particularly in recipients of double
UCBT, was encouraging (19%); (3) patients with
a standard risk of post-UCBT leukemia relapse had
51% LFS at 4 years; and (4) the use of 2 partially
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UCBT, particularly in adult recipients.
A non-MAC regimen was used for older patients,
heavily pretreated patients, and patients with signifi-
cant comorbidities. This conditioning regimen in-
cluded 5 days of fludarabine and single doses of ATG
and TBI (200 cGy). All patients received CsA and
MMF for posttransplantation immunosuppression.
Analysis of the outcomes of 188 patients compared
patients who received ATG with those who did not.
The data indicated no difference in primary neutrophil
recovery associated with ATG use. Nonrelapse mor-
tality (NRM) was higher in the patients who received
ATG; however, overall DFS was similar in the 2
groups.
In summary, (1) non-MAC UCBT shows repro-
ducible engraftment, low TRM, and encouraging
DFS;, (2) non-MAC UCBT extends the option of
this treatment modality to an older patient population;
(3) CB is a valuable alternative source of hematopoietic
stem cells (HSCs) for transplantation; and (4) double
UCBT extends UCBT to larger adolescents and
adults in both the MA and NMA settings.
Stefan Ciurea, MD, M.D. Anderson Cancer Center,
discussed conditioning regimens following the M.D.
Anderson approach. He reviewed (1) non–TBI-based
conditioning regimens used in UCBT, both busulfan
(Bu)-based and Mel-based; (2) experience with fludar-
abine Flu, melphalan Mel, and thiotepa (FMT) condi-
tioning; and (3) infectious complications in UCBT.
A total of 37 patients (28 adults and 9 children)
with advanced malignancy underwent UCBT with an
FMT conditioning regimen in 2 different protocols:
(1) a randomized trial of double UCBT with 2 arms,
1 arm with ex vivo expanded CB (CD1331 CB in
suspension culture) and (2) double UCBT, with 1 of
the 2 cords expanded in the presence of mesenchymal
stem cells (MSCs) for 14 days. Twenty-nine patients
received double CB units (19 ex vivo expanded
and 10 unmanipulated), and 8 patients received a
single CB unit. Results indicated engraftment in 34
of 36 (95%) evaluable patients, all of whom experi-
enced hematopoietic recovery with 100% CB-derived
cells. On day 30, 75% had chimerism from 1 CB unit,
whereas 25% had mixed chimerism between the
2 units. Median time to engraftment (ANC5 500)
was 21 days (range, 6-45 days); median time to
platelet engraftment was 35 days (range, 27-134 days;
n5 24; 67%). Of the 27 patients, 32 (87%) achieved
CR after transplantation, including all of the patients
with acute leukemia. The relapse rate was 26% after
a median of 7 months after transplantation. The day
100 TRM was 10%, and the NRM at 2 years was
32%. Sixteen patients (43%) survived after a median
follow-up of 12.1 months; causes of death were
relapsed disease (n5 9), infections (n5 10), and
GVHD (n5 2).The study’s conclusions can be summarized as fol-
lows: (1) The addition of thiotepa to FM140 appears to
provide optimal immunosuppression to allow a high
rate of engraftment in double UCBT, (2) FMT condi-
tioning is associated with low regimen-related toxicity
in these patients, and (3) the regimen provides an
alternative to TBI-based conditioning, with a balance
between antitumor effect and toxicity.
Dr Ciurea also discussed the high rate of primary
graft failure in haploidentical stem cell transplantation
(SCT) in the presence of donor-specific anti-HLA
antibodies (DSAs). Their experience indicated that
DSAs were detected in 5 of 24 consecutive patients
(21%). Four of the 24 patients had primary graft
failure, and 3 of the 4 patients with DSA (75%)
failed to engraft, compared with 1 of 20 patients
without DSA (5%) (P5 .008). More recent data
identified 12 patients with DSA, all multiparous
females who had received multiple blood transfusions.
These patients underwent haploidentical (n5 6),
matched unrelated donor (n5 3), or CB (n5 3) trans-
plantation. Overall, 7 of the 11 evaluable patients
(64%) failed to engraft the donor cells with a donor-
specific anti-HLA antibody. Accordingly, the role
of anti-HLA antibodies in UCBT merits further
investigation.SESSION III: GRAFT-VERSUS-HOST DISEASE,
INFECTION, AND RELAPSE AFTER
UMBILICAL CORD BLOOD
TRANSPLANTATION
Margaret MacMillan, MD, University of Minnesota,
reviewed GVHD after UCBT. aGVHD continues to
be a major cause of morbidity and mortality after allo-
geneic transplantation. After BMT, 50%-70% of pa-
tients develop grade II-IV aGVHD. Early data from
Eurocord and the Center for International Bone Mar-
row Transplantation Research (CIBMTR) indicate
that the incidence of grade II-IV aGVHD with sibling
donor UCBT is about half that with sibling donor
BMT. A publication by Dr. Eliane Gluckman, in
1997, (Gluckman E, et al. N Engl J Med. 1997;
337:373-381) indicated that the incidence of aGVHD
after related or unrelated donor UCBT was about half
that expected after BMT. A subsequent study of 399
evaluable patients from the New York Blood Center
in 1998 found a 44% incidence of grade II-IV aGVHD
following unrelated donor UCBT, again markedly
lower than what would be expected in BMT. In
2000, Barker et al reported a low incidence of aGVHD
in adults after unrelated donor UCBT using RIC (44%
grade II-IV; 9% grade III-IV). In 2008, Brunstein et al
reported that in 184 patients who underwent MA
UCBT, the incidence of grade II-IV aGVHD was
3%, and that of grade III-IV was 14%. A series of
161 NMA UCBTs reported in 2009 found a 54%
16 Biol Blood Marrow Transplant 16:12-27, 2010J. E. Wagner et al.incidence of grade II-IV aGVHD and an 18% inci-
dence of grade III-IV aGVHD.
A University of Minnesota study of 379 UCBTs
(210 single, 169 double) performed between 1994
and 2005, using both MAC and non-MAC regimens,
found a 60% incidence of aGVHD in double UCBTs
and a 33% incidence in single UCBTs. The incidence
in the double UCBTs was similar regardless of patient
age or cell dose. Only 7 patients received a 6/6 HLA-
matched single CB unit, and none of these patients
had GVHD, compared with the 66% incidence in
6/6 double UCBTs. The risk of aGVHD was higher
in the double UCBTs regardless of the degree of
HLA matching. Subsequent studies indicated that
the predominant difference in the aGVHD between
single and double UCBTs was the much higher inci-
dence of skin aGVHD in double UCBT.
Patients receiving a single UCBT with grade III-
IV aGVHD had poor survival (41%), but those receiv-
ing a double UCBT with grade III-IV aGVHD had
similar survival as patients receiving a double UCBT
with grade I or II GVHD (63%-67%).
Preliminary data are available from a University of
Minnesota study of allogeneic HCT in 615 patients
who underwent transplantation between 1994 and
2008. There were 188 matched sibling donor BMTs/
PBSCTs, 285 mismatched sibling or unrelated donor
BMTs/PBSCTs, 75 single UCBTs, and 67 double
UCBTs. Patients who received a single or double
UCBT or a matched sibling donor transplant had
a similar incidence of TRM (30%-33%), but those
who received a mismatched sibling or a matched unre-
lated donor transplant had a TRM of 51%.
The data indcate that the risk of aGVHD is lower
after single UCBT than after unrelated donor BMT,
despite 1 or 2 antigen disparities. This is true in both
children and adults and after both MAC and non-
MAC regimens. The risk of aGHVD is higher after
double UCBT than after single UCBT, and the
aGVHD is more frequently cutaneous in double
UCBT. Importantly, the higher risk of aGVHD after
double UCBT does not adversely affect survival. In
patients with severe aGVHD, TRM is lower in recip-
ients of double UCBT than in recipients of single
UCBT. In patients with aGVHD treated with ste-
roids, TRM appears to be lower in UCBT recipients
than in BMT/PBSCT recipients and is similar to
that in matched sibling donor BMT/PBSCT recipi-
ents.
Mary Eapen, MD, The Medical College of Wisconsin,
discussed the outcomes of a comparison study of unre-
lated donor UCBT and BMT in children with acute
leukemia. The study included 116 patients who received
a BMT and 503 patients who received a UCBT. All
patients had ALL or AML and were under the age of
16 years. The transplantations were performed between
1995 and 2003, and the median follow-up of survivorswas 5 years for BMT and 4 years for UCBT. All of the
BMT patients received an HLA allele-matched trans-
plant. In contrast, 7% of the CB transplants were
matched at the antigen level (6/6), and there was a
1-antigen mismatch in 40% and a 2-antigen mismatch
in 53%. The incidence of grade II-IV aGVHD was
50% in the BMT recipients (n5 116), 40% in the mis-
matched UCBT recipients (n5 454), and 20% in the
matched UCBT recipients (n5 35). The incidence of
cGVHD was 33% in the BMT recipients (n5 310)
and 17% in the matched/mismatched UCBT recipients
(n5 466). TRM was 6% in matched UCBT, 19% in
matched BMT, 29% in 1-antigen mismatched UCBT
with a high cell dose, 43% in 1-antigen mismatched
UCBT with a low cell dose, and 49% in 2- antigen
mismatched UCBT with a low cell dose. LFS was
60% in matched UCBT, 45% in 1-antigen mismatched
UCBT, 38% in matched BMT, 35% in 1-antigen
mismatched UCBT with a low cell dose, and 33% in
2-antigen mismatched UCBT with a low cell dose.
In summary, relative to matched BMT, matched
and 1-antigen mismatched UCBT with a high cell
dose had a lower incidence of GVHD and similar rates
of TRM, relapse, and LFS. Two-antigen mismatched
UCBT had a lower incidence of GVHD, a higher rate
of early TRM, a lower rate of relapse, and a similar rate
of LFS.
Paul Szabolcs, MD, Duke University, discussed
immune reconstitution after UCBT. The significance
of immune reconstitution is illustrated by data pub-
lished by Parkman et al. in 2006, indicating that acqui-
sition of herpes virus–specific immune response was
correlated with decreased leukemic relapse. Death be-
cause of an opportunistic infection (OI) is the primary
cause of death, with most occurring before 6 months
post-UCBT. Hematopoietic progenitor cells in CB
are involved primarily in innate immunity and recover
rather quickly within the first 30 days, as in BMT;
however, there is slower recovery of T and B cells,
which are involved primarily in adaptive immunity.
In a recent study, 330 consecutive pediatric recip-
ients of single UCBT performed between 1999 and
2005, 220 patients (67%) were alive at 6 months. An
OI (viral or fungal) was implicated as a cause of death
in 64 of the 110 children who died by 6 months (58%).
The 6-month death resulting from OI after single
UCBT in children can be predicted by the following
risk factors: older age, positive cytomegalovirus
(CMV) serology, or than 1 HLA mismatch, malig-
nancy without TBI, and lower graft cell dose (total,
CD341, and CD31). Sex, race, and TBI alone do not
predict 6-month death because of OI. The reasons
for impaired antimicrobial immunity after UCBT in-
clude T cell lymphopenia (because of preparatory reg-
imen and GVHD post-HCT), lack of previous antigen
exposure/priming (ie, naı¨ve cells), functional T lym-
phocyte and dendritic cell deficits in the graft, and
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limus, steroids, MMF).
A translational research objective is to enhance an-
tiviral immunity in the posttransplantation period by
alleviating T cell lymphopenia and functional T cell
deficits. Increased engraftment may occur through
improved homing, blockade of CD26, direct intraos-
seus injection, or administration of parathormone.
An increased total cell dose may be accomplished by
using double UCBT and by ex-vivo expansion of
stem/progenitor cells (eg, CLP, CMP, CD341,
ALDH1). Enhanced immune recovery may be accom-
plished by improving survival/homeostatic expansion
of infused lymphoid cells (eg, IL-7, rhu-GH); boosting
thymic output through thymus protection, thymo-
poietic agents, or thymus transplantation; correcting
Th1 hyporesponsiveness, reducing aGVHD (T regu-
latory cell therapy); increasing T cell dose/adoptive
T cell therapy; ex-vivo expansion of broad unprimed
T cell repertoire; and antiviral cytotoxic T lymphocyte
generation in vitro. These exciting approaches are cur-
rently being investigated internationally and will be
the focus of future discussions.SESSION IV: NONHEMATOPOIETIC USES OF
CORD BLOOD/REGENERATIVE MEDICINE
Jan Nolta, PhD, University of California Davis,
presented a review of nonhematopoietic uses of CB.
Efforts are underway to cure disease and repair and
regenerate damaged tissues and organs. Adult stem
cells are being compared with human embryonic
stem cells (ESCs) and induced pluripotent stem cells
(PSCs). Animal models are being used, including
human cells in immunodeficient mice, large-animal
models (eg, canine, equine), and nonhuman primate
models in anticipation of future clinical trials.
A search was conducted for a marker of conserved
stem/progenitor cell function that transcended cell
surface phenotype and was not restricted to a ‘‘cell
type,’’ such as HSCs versus MSCs. The enzyme alde-
hyde dehydrogenase (ALDH), for which nontoxic
isolation methods are available, was a safe candidate.
ALDH hi cells have a robust hematopoietic capacity
in vivo and also contain endothelial and early MSC
progenitors.
Advanced peripheral artery disease can result in
skin breakdown (ie, ulcers or gangrene) or foot pain
even at rest, and can lead to limb amputation in severe
cases. A femoral artery ligation model for the induc-
tion of acute ischemic injury was developed in
NOD/SCID B2 M null mice. An ALDH(hi) popula-
tion promoted almost complete correction by day 21,
in contrast to an ALDH(lo) population, which did
not significantly restore blood flow. Based on this
work, a clinical study has been successfully completed,
and the group of treated patients experienced improve-ments in overall clinical status as well as increased
blood flow in the affected limb.
An experimental left anterior descending cardiac
artery ligation model was developed for acute myocar-
dial infarction (AMI) in immunodeficient mice. Intra-
venous CB infusions were given 24 hours after injury
to 3 groups: peripheral blood stem cells (PBSCs),
ALDH(lo), and ALDH(hi). Analyses of cell tracking
were performed, including histology, immunohisto-
chemistry, in vivo and/or ex vivo cell tracking, and
functional parameters. The results indicated the pres-
ence of human cells in NOD/SCID/MPSVII mouse
cardiac tissue, along with a dramatically increased vas-
cular density in hypoxic tissue that was increased by
transplantation of ALDHhiLin-(A) cells, but not
ALDHloLin-(B) cells, sorted from human CB. In ad-
dition, an ongoing collaboration is underway to exam-
ine human stem cell–mediated repair of stroke.
In summary, adult stem cells act as the body’s
‘‘paramedics.’’ They migrate rapidly to regions of hy-
poxic tissue damage and inflammation and secrete
factors that enhance repair and revascularization.
This is accomplished in most cases through secretion
of factors acting in a paracrine manner, rather than
by direct tissue replacement. Stem cells from BM or
CB can provide effective therapy for regenerating
damaged and diseased tissues.
Wise Young, MD, Rutgers University, discussed
progress in the treatment of spinal cord injury (SCI)
using CB stem cells. An SCI clinical trial network
has been developed in China (ChinaSCINet), and in
response to numerous requests, a North American
Spinal Cord Injury Network is under development in
the United States. ChinaSCINet has 25 leading SCI
centers in mainland China, Hong Kong, and Taiwan
and can randomize 6000 subjects with acute SCI and
almost unlimited numbers of those with chronic SCI
each year.
Several groups have reported improved function
after injection of human cells into the contused spinal
cord. Major therapeutic goals are to bridge the injury
and provide sustained growth factor support. Only
a small proportion of the axons in the spinal cord
need to be regenerated to reach the threshold level
for recovery of function. The expectation is that cellu-
lar bridges with cell transplants will form a living bridge
across the injury site, supporting axonal growth across
otherwise inhospitable terrain. This bridge need not be
permanent. After the axons have grown past, the bridge
can quietly disappear after several months.
The use of CB cells to accomplish this was chosen
based on the results of preclinical studies showing that
intravenous infusion of human CB improves function
in a rat SCI model, intraspinal transplantation of
human CB CD341 cells improves recovery in hemi-
sected rats, intraspinal transplantation of human CB
CD341 cells plus brain-derived neurotropic factor
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CD341 cells survive for 3 weeks in contused rat spinal
cords and reduce tissue damage, and transplantation of
human CB mononuclear cells (MNCs) in contused rat
spinal cords improve locomotor recovery. Various re-
ports have documented that lithium and chondroiti-
nase stimulate spinal cord regeneration by inhibiting
glycogen synthetase kinase beta-3 (GSK-3ß), which
inhibits nuclear factors WNT-beta-catenin and
NFAT, which turn on growth programs.
As result of the foregoing preliminary work and
observations, 5 ChinaSCINet trials were conducted:
(1) CN100, a Phase 0 observational study of 600
patients with SCI and collected data for up to 1 year;
(2) CN101, a Phase 1 opened-label lithium trial evalu-
ating a 6-week course of daily oral lithium treatment
of 20 subjects with chronic SCI; (3) CXN102a, a Phase
2 lithium versus placebo double-blinded trial random-
izing 80 subjects with chronic SCI to lithium versus
placebo; (4) CN102b, a Phase 2 trial of escalating
dose CB mononuclear cell (CBMC) dose evaluating
the safety and efficacy of transplantation of 1.6, 3.2,
and 6.4 million HLA-matched CBMC cells to the
spinal cord of 40 subjects with chronic SCI, with
methylprednisolone and lithium; and (5) CN103, a
Phase 3 trial of HLA-matched CBMC transplantation
with and without lithium that will randomize 400 sub-
jects who received a CBMC transplant to lithium or
placebo.
Joanne Kurtzberg, MD, Duke University, discussed
the treatment of neurologic disorders with CB stem
cells. The mechanisms through which CB effectively
treats neurologic disorders include cell migration to
brain, cellular enzyme replacement therapy in meta-
bolic disease, cellular repair and regeneration in brain
injury and metabolic diseases (by stimulating autolo-
gous cells and replacement by allogeneic cells), and
suppression of inflammation.
The discussion included the treatment of inherited
metabolic disease with standard MA transplantation
and possibly fetal transplantation. Also discussed was
the treatment of various types of brain injury, includ-
ing hypoxic newborn encephalopathy, cerebral palsy,
congenital hydrocephalus, and acute brain injury (eg,
drowning, trauma).
A total of 160 children with inborn errors of
metabolism have been treated with CB transplanta-
tion. The preparative regimen consisted of Bu/Cy/
ATG, and GVHD prophylaxis was with CsA/steroids.
Supportive care included empiric antibiotic agents
with fever, antifungals, antivirals, Pneumocystis carinii
pneumonia prophylaxis, intravenous immunoglobulin,
granulocyte colony-stimulating factor (G-CSF), total
parenteral nutrition (TPN), transfusions (14 packed
red blood cells (PRBCs), 50 platelets), and low-dose
heparin for veno-occlusive disease (VOD) prophylaxis,
and percutaneous coronary angioplasty. Analysis oftransplantation outcomes included neurologic func-
tion, not just survival. Outcome analysis indicated
improved clinical outcome that altered the natural his-
tory of the disease, which otherwise would be neuro-
logic degeneration and early death.
Autologous transplantation is being studied in
cerebral palsy (CP), hypoxic newborn encephalopathy,
congenital hydrocephalus, and other brain injuries.
To date, 108 patients have been treated (73 with CP,
18 with hydrocephalus, and 7 with brain injury).
The median follow-up is 8 months. Preliminary
results show that 10 children with CP evaluated
1 year posttransplantation demonstrated improved
gross motor function measure scores. Anecdotal im-
provement was noted in congenital hydrocephalus on
neurosurgery, and 4 babies with hypoxic newborn
encephalopathy at. 24 hours of age improved. These
results indicate that the efficacy of this approach in
treating CP cannot be addressed without a randomized
trial.SESSION V: NEW CONSIDERATIONS IN
CORD BLOOD UNIT SELECTION
Juliet Barker, MD, Memorial Sloan-Kettering Cancer
Center, presented information indicating the signifi-
cance of a 6/6 match in UCBT. The impact of cell
dose and HLA matching on the survival of 1068
patients undergoing single UCBT for a hematologic
malignancy was analyzed. The hypothesis under con-
sideration was that better HLA matching compensates
for low TNC dose.
Results of outcome analyses demonstrated that 6/6
matched UCBTs (0 mismatches; 0 MM) are associated
with improved engraftment (P \ .001). Improved
HLA matching also is associated with less severe
aGVHD, but neither TNC dose nor HLA matching
was associated with the risk of relapse. The impacts
of TNC and HLA matching on survival were driven
by their impacts on TRM; thus, TRM was a major
focus of the analysis.
A higher TNC count was shown to be associated
with improved TRM, although there was no difference
if the TNC count was. 5.0 107/kg. Better HLA
matching was associated with progressively lower
TRM, and 0 MM was associated with the lowest
TRM (dose range, 0.7-19.4 107/kg). An analysis of
the combined effects of TNC dose and HLA matching
on TRM indicated that the best outcome was not
a high TNC count, but rather 0 MM. Further analysis
indicated that 0 MM was followed by 1 MM with
a TNC dose. 2.5 107/kg and 2 MM with a TNC
dose. 5.0 107/kg, and finally 2 MM with a TNC
dose of 2.5-4.9 107/kg. The worst outcomes were
seen with 1-2 MM with a TNC dose\2.5 107/kg
or 3 MM transplants. DFS analysis revealed similar
findings.
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UCBT are with 0 MM (6/6 match) units regardless
of dose, with better engraftment, less aGVHD,
reduced TRM, and improved survival. Further find-
ings indicate that mismatch does not protect against
relapse. A match can compensate for low TNC dose;
0 MM units and 1 MM with a TNC dose of 2.5-
4.9 107/kg is equal to 2 MM with a TNC dos-
e. 5.0 107/kg. Unit selection guidelines that result
from this analysis are 0 MM, 1 MM with a TNC
dose of$ 2.5 107/kg, and 2 MM with a TNC dose
of$ 5.0 107/kg (sliding scale). Limitations of the
study are that the threshold for an adequate TNC
for 0 MM units is not known. One should use units
with a TNC of unknown-use units \1.5 107/kg
with caution. Also, it should be noted that most adults
and adolescents have no ‘‘optimal’’ units (0 MM,
1 MM wih a TNC dose$ 2.5 107/kg, or 2 MM
with a TNC dose$ 5.0 107/kg) and that even
some ‘‘optimal’’ units do not engraft because of unit
quality, the patient’s ability to reject, and posttrans-
plantation infections. To address these problems, the
conditioning regimen/immunosuppression should be
optimized and double UCBT performed to increase
the likelihood of at least one unit having the potential
for engraftment. Finally, the inventory should be
enlarged with units of high quality, adequate dose,
and adequate HLA matching to provide at least 5/6
matched units for transplantation.
Jeffrey Miller, MD, University of Minnesota, dis-
cussed the effect of killer immunoglobulin receptor
ligand (KIR-L) alloreactivity in UCBT. After BMT
or UCBT, natural killer (NK) cells are markedly
increased, which is associated with diminished func-
tion. Previous studies have shown a benefit of KIR-L
mismatch in transplantation for AML using T cell–
depleted grafts, whereas other studies using mostly un-
manipulated BM grafts have shown no benefit. NK cell
alloreactivity has been associated with decreased re-
lapse and prolonged survival in MA T cell–depleted
adult haploidentical transplantation. Also, T cell re-
covery is slower after UCBT than after adult donor
transplantation. These findings led to the development
of the hypothesis that UCBT would favor NK cell al-
loreactivity, and the use of KIR-L mismatched units
could result in better clinical outcomes. In a study of
257 patients with hematologic malignancies who un-
derwent UCBT between 1998 and 2006, KIR-L mis-
matching in the GVHD direction was assigned based
on Bw4 and C1/C2 group mismatches. Two cohorts
consisted of patients who underwent MAC and non-
MAC UCBT.
The results indicate that in MAC UCBT, KIR-L
mismatch had no effect on GVHD, relapse, TRM,
or OS. This is in contrast to results for RIC UCBT,
in which the incidence of grade II-IV aGVHD was
significantly increased (P \ .01), TRM was lower(P5 .03), and OS was reduced (P5 .03); relapse was
not affected. Thus, the data do not support selection
of KIR-L–mismatched CB units for transplants
performed using RIC. These results are controversial,
however; other investigators have concluded that
KIR-L incompatibility in the GVHD direction
improves outcome after transplantation in acute leuke-
mia, especially AML (Leukemia 2009;23:492-500).
Stephen Spellman, MS, National Marrow Donor
Program, presented data indicating that the detection
of donor-directed, HLA-specific alloantibodies in
recipients of unrelated HCT is predictive of graft fail-
ure. Alloantibodies directed against mismatched HLA
antigens are a well-established significant risk factor in
solid organ transplantation (ie, renal, cardiac, and pan-
creatic), and previous studies in humans and recent
animal studies have indicated a role of DSAs as a risk
factor for rejection of HCT.
A retrospective, case-controlled study was per-
formed of BMT recipients who received an unrelated
stem cell transplant facilitated through the National
Marrow Donor Program (NMDP). A total of 37 pa-
tients and 78 case-matched controls (2-3 to 1) were
evaluated. Serum samples were tested in 2 different
laboratories by solid-phase microparticles, with 10%
of the samples tested in both laboratories for quality
control purposes. If HLA antibody screening was
positive, then HLA specificities were determined. All
donors and recipients were typed for HLA- A, -B,
-Cw, -DRB1, -DQB1, -DQA1, -DPB1, and -DPA1
to the allele level using high-resolution molecular
techniques. Patients were considered to have DSAs if
there was antigen or allele mismatch in the graft rejec-
tion direction and the recipient had antibodies against
the mismatched antigen/allele.
There was a lack of association between the pres-
ence of HLA antibodies and graft failure, but a positive
association between the presence of DSAs and graft
failure (P5 .0002). Nine of the 37 patients with a failed
graft had DSAs, compared with 1 of 78 patients in the
control group. This study concluded that the presence
of donor-specific HLA antibodies against HLA-A, -B,
and/or -DP as determined by solid-phase testing is
associated with graft failure, and that HLA antibody
evaluations should be a part of the routine workup
for unrelated BMT.
In UCBT, 2009 data from the European Group for
Blood and Marrow Transplantation for 648 patients
indicate a panel reactive antibody (PRA)-negative inci-
dence of 70%, a PRA-positive incidence of 24%, and
a DSA incidence of 6%. Respective engraftment rates
at day 1100 were 79%, 69%, and 50% (P\ .0001).
These findings indicate that anti-HLA antibodies
are fairly common in UCBT recipients, that the
presence of DSAs as determined by solid-phase testing
is associated with lower engraftment and graft failure
in UCBT, and that HLA antibody evaluations
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mismatched stem cell transplantations.
Andromachi Scaradavou, MD, Memorial Sloan-
Kettering Cancer Center, discussed the effect of CB
unit mononuclear cell (MNC) dose on transplantation
outcome and its relevance to processing method and
CB unit selection. At present, precryopreservation
TNC is used as an indicator of engraftment potential
in CB unit selection (National Cord Blood Inventory
[NCBI]-eligible, $ 900 106). However, TNC con-
tent may be affected by the CB processing method.
The AXP processing system results in loss of granulo-
cytes (20%), but. 97% recovery of MNCs, as well as
excellent colony-forming unit (CFU) and CD341 cell
recovery and viability. Therefore, evaluating a CB unit
on the basis of TNC after AXP processing can result in
an erroneous impression because of the loss of granu-
locytes but no loss of MNCs. A hypothesis suggests
that MNCs (mononuclear and nucleated red blood
cells [RBCs]) dose may be equivalent to, or even better
than, TNC dose as an indicator of CB unit quality for
engraftment and survival, for CB unit selection for
transplantation, and for NCBI eligibility. To test this
hypothesis, a study was performed, which indicated
that (1) both TNC and MNC values correlated with
CD341 cell dose, (2) engraftment rates were related
to the number of TNCs or MNCs, and (3) lower
TNC and MNC doses lead to higher TRM. To sum-
marize, the MNC content of CB grafts is a component
of TNC count; it can be easily standardized among CB
banks and is not affected by AXP processing. MNC
dose was found to be a good predictor of time to abso-
lute neutrophil count. 500 and TRM, equivalent to
or better than TNC when analyzed together. Thus,
MNC content can be used instead of TNC as an
indicator of CB unit quality and in CB unit selection
for transplantation, as well as in determining NCBI
eligibility.SESSION VI: SELECTING THE OPTIMAL
CORD BLOOD UNIT
Effie Petersdorf, MD, Fred Hutchinson Cancer
Research Center, discussed optimal HLA matching in
UCBT. Three critical questions are (1) whether the
current 3-locus HLA-A, -B, and -DRB1 definition is
adequate; (2) whether CB units should be selected
for high-resolution (allele) identity; and (3) whether
additional loci should be considered. Much of our
present knowledge is derived from experience with
adult unrelated donor transplantation. Careful dissec-
tion of genetic factors requires large, ethnically diverse
transplant populations with complete genetic and clin-
ical data. An international histocompatibility working
group in HCT had a database of 17,341 (16,198
accepted) unrelated transplantations as of September
2008. A comparison of the incidence of aGVHDamong ethnic groups was performed using a database
of 5555 pairs who received an HLA allele–matched
transplant (10/10 match). The results indicated that
patients receiving products obtained from same-race
donors had improved outcomes (ie, less aGVHD and
improved OS). With high-resolution HLA typing
has come the realization that phenotypic identity
does not equal genotypic identity. Allele disparity is
expected in race-matched pairs, and even more allele
disparity is expected in race-mismatched pairs. In
UCBT, there is a significant association between the
number of HLA disparities and cell dose. Preliminary
data in UCBT indicate that the various HLA loci do
not contribute equally to outcome. In summary,
many unanswered questions remain, including
(1) whether the risks associated with class I mismatch-
ing differ from those associated with class II;
(2) whether there are locus-specific risks; (3) whether
outcome can be improved by adding HLA-C, -DQ,
or -DP into unit selection; (4) whether among HLA-B
mismatches, does simultaneous HLA-C mismatching
account for additional risk/benefit; (5) whether among
HLA-DRB1 mismatches, does simultaneous DQB1
mismatching account for additional risk/benefit; and
(6) whether antigen-level and allele-level mismatches
confer different risks.
Eliane Gluckman, MD, Hoˆpital Saint-Louis, Paris,
France, reviewed HLA and cell dose considerations in
selection of CB units for transplantation. The data
indicate a significant correlation between TNC and
CD341 cell dose. The median TNC loss after thawing
is 25%, and the median CD341 cell loss after thawing is
15%. Measurement of CD341 cells at infusion pro-
vides a better indication of transplantation results. A
study in children with acute leukemia indicated that
the probability of neutrophil engraftment increased
with cell dose (TNCs or CD341 cells) up to a point,
after which increased doses did not alter the probability
of engraftment. An analysis of the interaction of
CD341 cell dose and HLA mismatch indicated that
patients who receive a low cell dose and have HLA
mismatches have poorer engraftment rates. Patients
with 3-4 HLA mismatches and a low cell dose had
poorer OS than patients with higher cell doses, in
whom the number of HLA mismatches had little effect.
An important question is whether HLA allele typ-
ing is important in UCBT. Two small studies resulted
in differing conclusions. A study by Willemze et al
regarding the impact of inhibitory KIR-L incompati-
bility found that unrelated, single UCBT from
KIR-L–incompatible donors in patients with acute
leukemia in CR resulted in a lower relapse rate and
higher LFS and OS. These results were more evident
for patients with AML. These data are not comparable
with the findings reported by Brunstein et al. (Blood,
2009). Numerous differences between the 2 studies
included included conditioning regimens and use of
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tively small, additional studies are needed to allow
definite conclusions.
The present recommendations for donor choice
are as follows:
1. Look at the number of cells ($ 2.5 107 TNCs/kg
and/or$ 1.5 105 CD341 cells/kg).
2. Look at HLA matches. None or 1 MM is better
than 2 MMs; avoid 3-4 MMs. Class I MMs are
preferred over class II MMs; this does not matter
in advanced disease. In double UCBT, the number
of HLA disparities and ABO compatibility appar-
ently are important as well.
3. Adapt to graft indication. For malignant disease, cell
dose is the best prognostic factor, because HLA
differences reduce relapse (ie, graft-vs-leukemia
effect). For nonmalignant diseases, increase the
cell dose ($ 4.0 107 TNCs/kg) and find the best
HLA match; search for antibodies against HLA.SIMULTANEOUS SESSION IA: CORD BLOOD
PROCESSING AND EVALUATION OF
POTENCY
John McMannis, PhD, M.D. Anderson Cancer
Center, reviewed CB processing methods and quality
assessment. Assessing the quality of individual CB
units is obviously important, but no one has yet solved
the problem of how to do this. Available precryopre-
servation processing methods include manual, manual
by gravity, plasma depletion, PrepaCyte, Sepax, and
AXP. Analysis of 1383 CB units prepared by the man-
ual centrifugation method indicated a TNC recovery
of 1.06 0.4 109; with gravity separation, the recov-
ery was 1.546 0.5 109. The plasma depletion
method results in a high proportion of CB units with
a high TNC count. In the NMDP inventory, the ratio
of plasma-depleted CB units to RBC-depleted units
with TNC counts of 125, 150, and 200 107 was
1.67, 2.0, and 3.0, respectively (P\ .0001). PrepaCyte,
a proprietary cell separation technology designed for
processing CB, results in TNC recovery ranging
from 78.8% 6 3.1% to 94.9% 6 6.8%, depending
on the ethnicity of the donor. CD341 recovery rates
range from 91.9% 6 10.5% to 101.9% 6 27%. AXP
and Sepax are 2 other automated CB processing
methods. A comparison of manual separation methods
(n5 1383) with the Sepax automated method
(n5 4149) revealed similar results in cell recovery,
except for a lower final RBC volume with the Sepax
method. In addition, the processing time was 30 min-
utes for the Sepax method, in contrast to 60 minutes
for the manual method. (No data were presented
regarding cell recovery using the AXP method.)
Assays for quality assessment of individual CB
units are critical, but have been difficult to develop.Good Manufacturing Practice (GMP) requirements
state that the manufacturing facility must have release
criteria for sterility, purity, identity, and potency. The
development of potency assays has proved to be the
most problematic. Clinical outcomes provide data
too late. Appropriate laboratory tests include TNCs,
CD341 cells, CFUs, and HLA. Some data indicate
that postthaw CD341 cells and postthaw CFUs pro-
vide good data regarding the quality of a CB unit. A
study of postthaw cell recovery of units from various
CB blood banks indicated rather consistent results, at
about 85%. The processing method had no significant
effect on the cell recovery.
Robert Chow, MD, StemCyte International Cord Blood
Center, Covina, CA, discussed CB unit selection, cover-
ing engraftment, GVHD, and OS using CB units
processed using the plasma depletion method. In vitro
studies indicate that the postprocessing yield of
plasma-depleted CB units appears to be associated
with significantly higher recovery for TNCs, CD341
cells, CFU-GM (granulocyte, monocyte), CFU-
GEMM (granulocyte, erythrocyte, monocyte, mega-
karyocyte), nucleated RBCs, and RBCs in parallel
processing comparisons between plasma depletion
and HES red cell reduction of the same CB unit
(n5 10). There were no statistically significant differ-
ences for MNCs and CFU-e. Outcome studies of
plasma-depleted UCBT stratified by HLA matching
or TNC dose indicate that outcomes for neutrophil
and platelet engraftment, TRM, relapse rate, OS, and
DFS appear to be at least as good as those in the study
by Eapen et al. (Lancet, 2007) of single UCBT in pa-
tients with AML or ALL. Accordingly, the suggestion
that a 30% discount in cell dose should be applied to
non–RBC-reduced CB units does not seem to have
a basis for plasma-depleted CB units. A rigorous
matched-pair retrospective or prospective comparison
is needed to confirm these observations.
The significance of postthaw washing of plasma-
depleted CB units was investigated using matched-
pair analysis. Preliminary conclusions are that
improved engraftment, TRM, OS, and DFS are asso-
ciated with the use of nonwashed plasma-depleted CB
units; the incidence of aGVHD grade III-IV is similar
for washed and nonwashed plasma-depleted units;
a lower incidence of extensive cGVHD is associated
with nonwashed plasma-depleted units; and the re-
lapse rate is similar for nonwashed and washed units.
Studies were performed regarding the effect of
GVHD on engraftment, TRM, relapse, OS, and DFS
of GVHD following transplantation of washed or
nonwashed plasma- depleted units. The results indi-
cate that for both washed and nonwashed units, grade
I-II aGVHD is associated with improved engraftment,
TRM, OS, and DFS in patients with malignant or non-
malignant indications versus patients with no aGVHD.
Moreover, grade III aGVHD is associated with
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nant or nonmalignant indications versus patients with
no aGVHD. Further findings indicate that limited
cGVHD is associated with improved engraftment,
OS, and DFS in patients with malignant or nonmalig-
nant indications and improved relapse rates for patients
with malignant indications versus those without
cGVHD. These improvements in patients receiving
unwashed CB units may result from the higher percent-
age of patients with limited cGVHD and the lower per-
centage of patients with extensive cGVHD.
Joanne Kurtzberg, MD, Duke University, presented
data regarding CB unit CFUs, ALDHbright cells, and
engraftment. Methods of CB processing include dilu-
tion and freezing (contains all components), plasma
depletion (contains leukocytes and RBCs), RBC and
plasma depletion (contains residual RBCs and MNCs),
and separation of MNCs (contains MNCs and few
RBCs). In addition, there are many methods for CB
unit thawing and infusion, including direct infusion;
dilution and infusion; and dilution, washing, and infu-
sion. A multivariate analysis was performed to deter-
mine which tests best predicted OS and engraftment.
The best tests for both survival and engraftment
were postthaw CFUs (P\ .0001 and # .0001, respec-
tively) and postthaw CD341 cells (both P 5 .01). But,
CFU assays require a colony culture over 14-16 days,
and the assay is hard to standardize. A possible solution
is to define/develop rapid assays that correlate with the
CFU content of CB units assessing viable cells. Data
indicate that ALDHbright cells correlate well with
CFUs. Accordingly, a prospective multicenter study
is underway to determine which studies on thawed
segments can predict engraftment (potency) of a
banked CB unit. The hypothesis is that ALDHbright
content/dosing measured in segments from CB units
will best correlate with engraftment.SIMULTANEOUS SESSION IB: CORD BLOOD
BANKING ISSUES AND FEDERAL SUPPORT
Lawrence Petz, MD, StemCyte International Cord
Blood Center, Covina, CA, discussed underutilization
of HCT, exploring the extent of the problem, causes,
and proposed strategies for improvement. An article
by van Rood and Oudshoorn (BMT 2008;41:1-9)
pointed out that data in the Bone Marrow Donors
Worldwide registry indicate that of 151,000 patients
qualifying for an HLA-unrelated donor transplanta-
tion between 2000 and 2006, only 64,720 received
one. Thus, 86,280 patients who qualified for a trans-
plantation did not receive one. Data from the
CIBMTR indicate that 10,260 related donor trans-
plants were performed in 2006. Considering the fact
that only about 30% of persons needing a transplanta-
tion have a matched related donor, there should be
about 2.3 times as many matched unrelated donortransplantations, or, in this case, 23,940 transplanta-
tions. But, only 8350 transplantations were actually
performed, indicating that 15,590 patients who needed
a transplantation did not receive one in 2006.
Kollman et al. (BMT 2001:27:581-587) reviewed
the results of a prospective survey of 544 searches of
the NMDP registry and concluded that the most fre-
quent causes of nontransplantation were patient death,
worsening medical condition, and the lengthy search
process. Two recent publications indicated that by
the time a donor is finally found, 30% of patients
have relapsed or are otherwise unfit for transplanta-
tion. It is evident that in these cases, the transplant
physicians did not appropriately utilize the option of
UCBT, because CB units can be obtained in a matter
of only days to weeks. Physician attitude is an impor-
tant factor in underutilization. Not all BMT-eligible
patients are referred for HCT consultation, and
HCT may be utilized too late in the course of therapy
as a treatment of last resort.
To decrease utilization, the search process should
be made as fast and convenient as possible, transplant
physicians must be made aware that CB units can be
obtained quickly, and searches for donor units should
include CB registries from the onset. Also, some recent
publications suggest that transplantation should not
be deferred because of the lack of a matched related
donor.
Improving the outcomes of UCBT by using
better-matched units should lead to greater utilization.
At present, the NMDP supplies 6/6 HLA-matched
units for only 6% of adults and 19% of children. Stud-
ies indicate that increasing the inventory of CB units is
cost-effective, and an emphasis on this is needed.
Finally, indications for HCT should be extended
to the elderly, persons with high-risk disease, and
the 300,000 persons born annually who are lethally
affected homozygotes with thalassemia or sickle cell
disorder.
Dennis Confer, MD, National Marrow Donor Pro-
gram, discussed the NMDP’s goal of facilitating
10,000 HCTs annually by the year 2015. The use of
UCBT continues to increase. The NMDP registry
now has 102,000 CB units and 7,680,964 adult donors.
In recent years, there has been a dramatic increase in
HCTs facilitated by the NMDP, because of increased
utilization of PBSCT and UCBT.
There has been a steady improvement in 1-year
survival (based primarily on adult HCTs), increasing
from 42.2% for 1997-2001 to 48.8% for 2000-2004,
51.5% for 2001-2005, and 54.0% for 2002-2006. The
most recent data (2005-2006) indicate essentially
equivalent outcomes from HCTs using matched unre-
lated donors and those using matched related donors.
Estimates of the need for unrelated donor trans-
plants are as follows: inferred from the search activity,
9000; inferred from the matched sibling transplants,
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11,500. None of these estimates considers emerging
indications (eg, sickle cell disease, thalassemia, autoim-
mune disorders).
To summarize, there may be 10,000 candidates
annually for unrelated donor HCT in the United
States; the NMDP has set a goal of 10,000 HCTs in
2015 (perhaps 8,000 of these would be in the United
States); there are multiple barriers to meeting this
goal, including graft availability, financial issues, space,
and personnel shortages; and meeting the needs likely
will require increased numbers of CB units and adult
donors.
Juliet Barker, MD, Memorial Sloan-Kettering Can-
cer Center, discussed the ability of CB units to provide
stem cells for minority populations. Strict HLA
matching using high-resolution HLA-A, -B, -C, and
-DRB1 (-DQ) alleles improves the outcome of unre-
lated volunteer donor transplantation but limits the
donor pool. UCBT has a greatly reduced HLA
matching requirement ($ 4/6 HLA-A and -B anti-
gens, -DRB1 allele), and thus may extend the donor
pool. The hypothesis is that CB units will increase
the access to transplantation. A prospective study
was conducted of donor availability according to
patient ancestry, with patients grouped according to
country of origin. Of the 463 patients in the study,
64% were European and 36% were non-European.
A total of 186 patients did not undergo transplanta-
tion for reasons other than lack of available graft.
Fifty-nine of these patients were undergoing evalua-
tion at time of data analysis; reasons why the other
127 patients (27% of the cohort) did not undergo
transplantation included disease progression/treat-
ment complications (n5 82), family donor chosen
(n5 8), ineligibility for transplantation (n5 6),
underwent transplantation at another institution
(n5 20), patient preference (n5 10), and autologous
transplantation (n5 1). A majority of the northwest-
ern European patients received an unrelated donor
graft, and CB units contributed only slightly to the
ability to find a donor. In contrast, CB had a much
more significant impact on the ability to perform
transplantation in southern Europeans, Asians, Afri-
cans, and Hispanics. In particular, those who had no
other donor options included 12% of southern Euro-
peans and 57% of non-Europeans (18% Asian, 18%
African, 14% Hispanic, 2% Middle Eastern, and 5%
mixed non-European). In conclusion, unrelated donor
transplantation predominantly serves patients of
northwestern, eastern, and mixed European ancestry,
with many southern Europeans and non-Europeans
having no matched unrelated donors. The use of CB
extends the access to transplantation to all patients,
especially southern Europeans and non-Europeans.
Only 5% of patients have no available graft. Securing
a suitable graft is the most challenging for patients ofAfrican ancestry. These data provide compelling sup-
port for increased funding of public CB banking and
suggest that CB has the greatest potential to provide
an allograft for all patients regardless of race.
Robert Baitty, MPP, Health Resources and Services
Administration, reviewed federal government support
for CB banking. The aims of the C.W. Bill Young
Cell Transplantation Program are to increase the
number of unrelated donor transplantations, increase
patient survival after transplantation, increase the
number of adult potential donors and CB units, pro-
vide advocacy services for patients and donors, and
develop mechanisms for reporting and analyzing
transplantation outcome data. The present status of
the program that (1) contract components are fully
functioning; (2) there is continued growth in the num-
ber of adult donors and CB units available through the
program; (3) the number of transplants facilitated
through the program is increasing sharply (4330
transplantations facilitated in fiscal year (FY) 2008,
compared with 3679 transplantations in FY 2007—
an 18% increase); and (4) the program is on track
to meet the goal of facilitating 4500 transplantations
annually by the year 2010. (A total of 2310 baseline
transplantations were facilitated in the year 2003.)
Also, the program has already exceeded the goal of
636 transplantations in minority patients by 2010
(The number of transplantations done in FY 2008
was 111% of those done in FY 2003.) The program
is on track to improve patient outcome at 1 year post-
transplantation from 62% to 69% by 2010 (currently
68%) for standard-risk patients, and the stem cell ther-
apeutic outcomes database is collecting outcome data
on all allogeneic transplantations (not only unrelated
transplantations) and is developing an approach for
data collection on novel hematopoietic progenitor
cell–derived cellular therapy.
An advisory council on blood stem cell transplan-
tation has been developed to consider and make
recommendations to the Secretary of Health and
Human Services and HRSA on matters related to the
C.W. Bill Young Cell Transplantation Program and
the NCBI. This advisory council comprises 22 voting
members and 6 nonvoting members representing
a number of required categories, including CB banks
and transplantation physicians.
The NCBI was established by the Stem Cell Ther-
apeutic and Research Act of 2005. HRSA provided
funding for high-quality, diverse CB units, with a
target of 150,000 new units, and authorizes appropria-
tions of $15 million/year for FY 2007-2010. The fed-
eral funding is temporary until 150,000 CB units have
been collected.
Remaining challenges include meeting the annual
need for unrelated-donor transplantations; improving
transplantation outcomes, including CB for adults;
recruiting sufficient diverse bone marrow and
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can-American CB units; continuing support/incen-
tives for CB unit inventory growth; developing
a consensus on, and standardization of, measures of
potency for CB units; improving the timeliness and
completeness of outcome reporting, including product
quality and patient outcome data to CB banks; and
adapting to FDA licensure of CB. A website to dissem-
inate information about these activities is available at
http://bloodcell.transplant.hrsa.gov/.
J. Douglas Rizzo, MD, MS, CIBMTR, The Medical
College of Wisconsin, discussed the topic of optimizing
CIBMTR reporting. The center collects data on all
HCTs performed at participating centers. In addition,
‘‘comprehensive report form’’ data are collected for
selected patients (all BMT CTN enrolled subjects,
a percent of unrelated recipients, CB recipients, and
a percent of others). The purposes of these activities
include collecting data (and specimens) on all alloge-
neic HCTs with a US recipient or donor, developing
a related donor–recipient repository, and developing
a secure, efficient electronic data capture system.
Also, the data will be analyzed and disseminated within
the program, to the scientific and medical community,
and to patients, families, and the public. The data are
used for studies (56 peer-reviewed publications and
nearly 40 abstracts in 2008), for information requests
(an average of 60 per month), and to provide informa-
tion for clinical trials. The reporting requirements
place a significant burden on transplantation centers.
In general, centers performing fewer than 100 HCTs
annually have a median of 1 full-time equivalent to
complete data-related activities, compared with a
median of 3 full-time equivalents in centers perform-
ing 101-150 HCTs annually, with the number gener-
ally increasing for larger programs. The CIBMTR is
attempting to ease the reporting burden by appealing
for more resources, focusing attention on reviews of
systems and processes, and providing direct assistance.
The CIBMTR is committed to sharing the data
with centers, facilitating appropriate sharing by net-
works, and returning data back to centers as soon as
possible to use in RFI, FACT, QI, research, and other
uses. This will be accomplished through the ability
to query data and the use of AGNIS (A Growable
Network Information System).SIMULTANEOUS SESSION IIA: BASIC
SCIENCE/IMMUNOBIOLOGY
Sunanda Basu, PhD, Indiana University School of
Medicine, discussed strategies to improve homing and
engraftment. A major limitation to the use of CB grafts
in adults concerns the fact that these grafts have a
markedly reduced number of stem/progenitor cells
compared with BM or mobilized PBSC grafts. Ap-
proaches to this problem include multiunit transplan-tation, in vitro expansion of hematopoietic stem and
progenitor cells (HSPCs), and identifying molecular
pathways that underlie homing and engraftment of
HSPCs. Expermental data using mice indicate that
the process of homing is very inefficient; only 1%-
5% of transplanted cells home to the BM.
Studies have indicated that stromal-derived factor
1 (SDF-1)/CXCL12 plays an important role in hom-
ing and retention of HSPCs in BM. Basic studies
were carried out with protein phosphatase2A (PP2A)
(serine [ser]/threonine [thr] phosphatase) and okadaic
acid (OA), which has been found to be a specific ser/
thr phosphatase inhibitor. It binds to and inhibits
PP2A-C and PP1-C. However, in low doses it is con-
sidered to selectively target PP2A, but not other ser/
thr phosphatases. OA inhibits PP2A activity in
CD341 cells in a dose-dependent manner without af-
fecting viability. Inhibition of PP2A impairs chemo-
taxis of CD341 cells toward SDF-1. Expression of
constitutively active Akt in CB CD341 cells impairs
chemotaxis toward SDF-1. Association of Akt with
PP2A is enhanced following SDF-1 stimulation.
In summary, inhibition of PP2A impairs chemo-
taxis of CD341 cells toward SDF-1, which is associ-
ated with prolonged Akt phosphorylation. Cells
pretreated with OA do not polarize in response to
SDF-1. In addition, both the speed and sense of direc-
tion are impaired. Interaction of Akt with PP2A fol-
lowing SDF-1 stimulation is increased. b-arrestin-2
is found in the Akt–PP2A complex following SDF-1
stimulation. This raises the possibility that Akt–
PP2A interaction following SDF-1 stimulation in
CD341 cells is effectively mediated by b-arrestin-2.
One possible mechanism through which Akt affects
chemotaxis is by regulating GSK-3 activity.
Yan Liu, PhD, Memorial Sloan-Kettering Cancer
Center, explored the use of CB to identify cell cycle
regulatory targets for treating leukemia. Research
goals are (1) to define how transcriptional dysregula-
tion contributes to the pathogenesis of AML, (2) to
identify new molecular targets for therapy, and (3) to
understand basis for therapeutic failure in AML/
MDS. The t(8;21) translocation in human leukemia
generates a fusion protein (AML1/ETO), which func-
tions as a transcription repressor. Studies have deter-
mined that quiescence (G0) is a physiological state
occupied by ‘‘resting’’ cells that have exited the cell
cycle. The relative quiescence of HSCs may protect
these cells from DNA damage caused by reactive oxy-
gen species, chemotherapy drugs, or irradiation. HSC
quiescence is controlled by HSC-intrinsic mechanisms
and BM microenvironmental factors, cell cycle regula-
tors (PTEN, Rb, PML, and MEF), and stem cell niche
(angiopoietin/Tie2).
A reproducible system to express AML1-ETO in
human CB CD341 cells has been established. A critical
role of MEF and cyclin C has been defined in
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man CB HSCs (and murine HSCs) is a powerful way
to identify novel therapeutic targets for treating leuke-
mia. Therapeutic implications of this work are that de-
creasing cyclin C or MEF levels in human CD341 cells
may be useful for ex vivo stem cell expansion and/or
gene therapy, and eliminating tumor stem cell quies-
cence may promote tumor cell killing (targeting p57
and/or p53).
Linheng Li, PhD, Stowers Institute for Medical
Research, Kansas City, MO, discussed stromal niches
that distinguish reserved versus primed states of CB
HSCs. The ‘‘niche hypothesis’’ suggests a physically
limited microenvironment to support stem cells in
vivo. Experimental questions include: (1) What are
the molecular mechanisms that control the activation
of stem cells?; (2) does deregulation of the signal affect
stem cell maintenance and self-renewal?; and (3) does
the uncontrolled activation of stem cells have the risk
of tumorigenesis? Data indicate that PTEN maintains
normal HSCs and prevents the development of leuke-
mia stem cells. Moreover, PTEN inhibits stem cell
activation through suppression of Akt activity, and
Akt may aid Wnt signaling by phosphorylation of
b-catenin at the S552 site. HSCs with active b-catenin
and inactive PTEN leads to a dramatic expansion of
HSCs. There is a balance between HSC expansion
and leukemogenesis; mice with activated b-catenin
and PTEN deficiency rapidly develop leukemia. Phar-
macologic manipulation of the Wnt/beta-catenin and
PTEN/Akt pathways allows the ex vivo expansion of
HSCs.
In summary, (1) PTEN/Akt and Wnt/beta-catenin
interaction regulates HSC self-renewal, (2) genetic
deregulation of PTEN/Akt and Wnt/beta-catenin re-
sults in massive HSC expansion, (3) deregulation of
these pathways in HSCs eventually results in leukemia,
and (4) taking a pharmacologic approach could expand
normal (functional) HSCs in vitro.
Mariusz Ratajczak, MD, PhD, DSci, University of
Louisville Stem Cell Biology Program, discussed the opti-
mization of isolation and further molecular and func-
tional characterization of SSEA-41/Oct41/CD1331/
CXCR41/ LIN-/CD45- VSEL stem cells isolated
from UCB. The need exists for a safe, efficient, and
politically acceptable source of PSCs for regeneration.
An alternative explanation of stem cell plasticity is the
existence of primitive pluripotent cells in adult tissues,
which are responsible for some of the stem cell plastic-
ity data. Isolation and characterization of small Sca-
11lin-CD45- cells has indicated that they are very
highly enriched for several ESC markers and also
markers involved in the development of tissue commit-
ted stem cells. These cells are much smaller than HSCs
and are called VSEL stem cells. Data indicate that
VSEL stem cells are mobilized into peripheral blood
after AMI and stroke, and they are present in UCB.CB VSEL stem cells exhibit hematopoietic activity
when activated on an OP-9 feeder layer. Furthermore,
CB-derived VSEL stem cells may differentiate into
neural cells.
In conclusion, BM and other organs contain a pop-
ulation of pluripotent VSEL stem cells. Hypotheses
suggest that VSEL stem cells are deposited in organs
of young mammals early in the development as a reserve
pool of mobile epiblast-derived stem cells for tissue re-
pair and regeneration. Their proliferation is controlled
by methylation status of certain developmentally cru-
cial somatic imprinted genes; VSEL stem cells could
be released/mobilized from neonatal bone marrow
(and possibly other niches as well) and circulate in
CB; VSEL stem cells give rise to HSCs and MSCs;
VSEL stem cells may be a potential source of histocom-
patible stem cells for regeneration therapies.SESSION IIB: DISEASE-SPECIFIC OUTCOMES
AND NEWAPPROACHES IN CORD BLOOD
TRANSPLANTATION
Guillermo Sanz, MD, PhD, Hospital Universitario La
Fe, Valencia, Spain, provided data on UCBT for adults
with hematologic malignancies. Comparisons of
UCBT and BMT from matched unrelated donors in
adults with acute leukemia contain possible biases
favoring bone marrow. The center has less experience
with UCBT, and the choice of donor has been inade-
quate in CB unit selection in many instances (no guide-
lines until recently). This presentation emphasized
that improved outcomes can be obtained with new
MAC regimens and the inclusion of CD341 cell dose
in the criteria for CB unit selection. Results of the
Spanish GETH 2005 UCBT trial indicated fast
engraftment and low early NRM after single-unit
UCBT with a new MAC regimen (n5 83). The condi-
tioning regimen comprised thiotepa 5 mg/kg/day i.v.
in 4 hours on days -7 and -6; Flu 50 mg/m2/day i.v.
in 1 hour on days -5, -4, and -3; Bu 3.2 mg/kg i.v. in
3 hours on days -5, -4, and -3; and thymoglobulin
2 mg/kg/day on days -5, -4, -3, and -2. The cumulative
incidence of myeloid engraftment (polymorphonu-
clear leukocytes. 0.5 109/L) was 94% at a median
of 19 days, and that of platelet engraftment was 78%
at a median of 44 days. The incidence of aGVHD
grade III-IV was 11%, NRM was 13% at 100 days
and 22% at 180 days, relapse risk at 4 years was
19%, and DFS at 4 years was 41% (early disease,
52%; intermediate disease, 38%; and advanced dis-
ease, 18%). The main conclusion of this study was
that in multivariate analyses, conditioning with thio-
tepa, Bu, and Flu demonstrated faster myeloid and
platelet engraftment, a lower incidence of aGVHD,
and less NRM compared with other MAC regimens.
A single-center study of outcomes after single-unit
UCBT and MAC was performed in 104 adults with
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was the GETH 2005 regimen described above with
minor modifications. The cumulative incidence for
myeloid engraftment was 94% at a median of 20
days. Patients receiving. 2  105 CD341 cells/kg
had better engraftment rates than those who re-
ceived# 2  105 cells/kg. LFS at 4 years for patients
with high-risk AML in CR1 (n5 30) was 75% in those
receiving. 2  107 nucleated cells/kg and 25% in
those receiving# 2  107 nucleated cells/kg. In
high-risk ALL patients (n5 55), LFS was 35% at 2
years and 28% at 4 years. In summary, single-unit
UCBT with new MAC regimens and including
CD341 cell dose among the criteria for CB unit choice
in adults with hematologic malignancies improves en-
graftment and NRM and results in comparable long-
term outcomes to those reported with double UCBT.
Franco Locatelli, MD, University of Pavia, Italy,
reported on UCBT to treat childhood AML and
ALL. Eurocord data indicate that TRM in single
UCBT in children with malignancies (n5 847) has
been reduced from 32% in 1994-1999, to 17% in
2003-2006. OS has increased from 42% in 1994-
1998, to 47% in 2004-2008. Children not undergoing
transplantation until reaching advance disease status
decreased from 34% before 2000, to 27% in 2005-
2008. The percentage of UCBTs with. 2 HLA dis-
parities has decreased from 5% before 2000, to 1.5%
in 2005-2008. Event-free survival at 3 years is 45%
for patients undergoing transplantation in early dis-
ease, 38% for those in intermediate disease, and
32% in those in advanced disease. A survey of unre-
lated UCBTs in children with AML (n5 290) indi-
cated that LFS in children with single first UCBT
was 65% for patients undergoing transplantation
while in CR1, 45% for those undergoing transplanta-
tion while in CR2, and 22% for those undergoing
transplantation with advanced disease. A survey of
unrelated UCBTs in children with ALL (n5 665)
indicated that the probability of LFS at 2 years was
43% for patients undergoing transplantation while
in CR1, 37% for those undergoing transplantation
while in CR2, and 19% for those undergoing trans-
plantation with advanced disease. For UCBT in chil-
dren with ALL in CR2 (n5 282), a review of relapse
incidence according to whether the previous relapse
was on or off chemotherapy indicated the probability
of relapse was 59% when the relapse occurred while
on therapy and 26% when relapse occurred while off
therapy. LFS was 48% when the previous relapse
occurred while the patient was off therapy (n5 88)
and 32% when relapse occurred while the patient
was on therapy (n5 95).
Factors influencing the choice of type of HCT are
the urgency of transplantation, the disease necessitat-
ing transplantation, patient’s body weight, number of
cells available in the CB unit, HLA compatibility inthe donor recipient pair, NK cell alloreactivity, and
the center’s attitude.
Joanne Kurtzberg, MD, Duke University, reviewed
the topic of UCBT for metabolic disorders. CB is
probably the optimal graft source option for this group
of patients, because they are generally small children
and do not have cancer, so the lower risk of GVHD
is important. Moreover, CB cells may have greater
capacity for regenerative medicine than adult cells
from BM or PB. Much progress has been made in
UCBT since the first such transplantation was
performed in France in 1988. The first CB bank was
established in 1992, and the first unrelated transplanta-
tion was done in 1993. To date,. 15,000 transplanta-
tions have been performed, and there are. 100 CB
banks worldwide. Also, there is now some federal
government support for CB banking as part of the
C.W. Bill Young Cell Transplantation Program.
The mechanism through which UCBT corrects
inborn errors of metabolism is by replacing the
patient’s marrow with donor cells after BM immunoa-
blation. The donor leukocytes produce enzymes that
are distributed through the circulation. Also, cells
cross the blood-brain barrier and replace enzymes in
the brain. A review was conducted of the first 160 pa-
tients who underwent transplantation for inborn er-
rors of metabolism (median age, 1.61 years; range, 0-
24 years), including Hurler syndrome, Krabbe disease,
Sanfillipo syndrome, and Tay-Sachs disease. The pre-
parative regimen consisted of busulfan/cyclophospha-
mide/ATG, and GVHD prophylaxis was with CYA/
steroids. The children were a high-cell cohort, so out-
comes were not related to cell dose. CD341 cell dose
and especially CFU dose were important determinants
of outcome, however. Survival was significantly im-
proved by ethnicity matching (P 5 .05). Outcomes
were better in patients with 5/5 or 6/6 HLA-matched
units than in those with 3/6 or 4/6 HLA- matched
units.
In an attempt to obtain even better results, a study
investigating the use of ALDHbright cells isolated from
a portion of the graft in an effort to augment engraft-
ment is currently in progress. In addition, a study of
fetal transplantation is underway, because some
patients have prenatal damage that is not reversible
with a postnatal transplantation. In the ‘‘preimmune
fetus,’’ it may be possible to induce donor cell
tolerance without immunosuppression or chemother-
apy. Patients will include those with Krabbe, meta-
chromatic leukodystrophy, Tay-Sachs, or Sandhoff
disease.
Paul Szabolcs, MD, Duke University, presented data
on ex vivo expansion and Th1/Tc1 maturation of CB
T cells by CD3/CD28 costimulation. Of 330 consecu-
tive pediatric recipients of single UCBT between 1999
and 2005, 220 (67%) were alive at 6 months. The pre-
dominant cause of death was viral opportunistic
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Reasons for impaired antiviral immunity after
UCBT included T cell lymphopenia, lack of previous
antigen exposure/priming (ie, naı¨ve cells), functional T
lymphocyte deficits, and pharmacologic immunosup-
pression (eg, CsA, FK506). The research objective is
to enhance antiviral immunity in the posttransplanta-
tion period by alleviating T cell lymphopenia and
functional T cell deficits. Ex vivo T cell expansion of
a small portion of a CB graft (sacrificing no more
than 2%-5% of the graft) is a potential source of post-
transplantation donor leukocyte infusions (DLIs),
which could improve posttransplantation immunity
before thymic regeneration. Expanded T cells that
are viable, exhibit minimal cell death/apoptosis, and
demonstrate functional maturation toward Th1/Tc1
potential are ideal candidates for DLI. To maximize
expansion and cell viability, the objective is to optimize
the cytokine requirement by adding interleukin (IL)-7
to IL-2 in cell culture media, which can result in supe-
rior overall expansion by reducing apoptosis and/or
potentiating proliferation. Two different sources of
clinical-grade anti-CD3/CD28–coated Dynabeads
were tested to determine which of these artificial anti-
gen-presenting cells led to better overall T cell expan-
sion (‘‘control’’ academic GMP source vs ClinExVivo
[Invitrogen]). Results indicated that adding IL-7 to
the culture media afforded significantly better expan-
sion than IL-2 alone, and that significantly more viable
T cells were generated with ClinExVivoR beads irre-
spective of the presence or absence of IL-7. Proposed
mechanisms of how IL-7 may potentiate overall T cell
expansion are that T cells entering the cell cycle are en-
hanced with IL-7, and T cell apoptosis is simulta-
neously reduced in the presence of IL-7. The results
also indicate that despite the higher expansion rate in
IL-7, there is better preservation of the surface mole-
cules required for homing to secondary lymphoid or-
gans (eg, CD62L, CCR-7), along with preservation
of the ‘‘resting, naı¨ve’’ Recent thymic emigrants
(RTE) appearance. Irrespective of the presence or ab-
sence of IL-7, expression of Th1/Tc1 cytokines, gran-
zyme A and B, and perforin was enhanced compared
with day 0 pre-expansion; however, they did not reach
the values seen in adult PB. Lack of cytotoxicity against
allogeneic targets (eg, IM9 cells, recipient fibroblasts)
may indicate reduced potential for inducing GVHD
after adoptive transfer (ie, DLI). Current and future di-
rections of research include ongoing large-scale T cell
expansion in a GMP facility and optimization of the
freeze/thaw procedure in preparation for a phase I trial
involving infusion of expanded T cells into recipients
to bolster immune reconstitution and reduce OI-
related mortality.Partow Kebriaei, MD, M.D. Anderson Cancer Center,
discussed the addition of CB to RIC regimens to aug-
ment the graft-versus-tumor (GVT) effect. Peripheral
blood progenitor cell (PBPC) transplantation with
RIC regimens is associated with a low TRM and dura-
ble engraftment, but relapse remains the major cause of
treatment failure. Thus, the challenge is to increase the
GVT effect without increasing GVHD. A Phase 2 study
explore the addition of a CB unit to RIC allogeneic
PBPC transplantation to augment GVT for advanced
hematologic malignancies. The hypothesis was that
a single CB unit will transiently engraft and augment
the GVT effect, while durable hematopoietic recovery
will result from PBPCs obtained from a separate alloge-
neic HLA-matched adult donor. The RIC regimen was
a Flu 120 mg/m2 and Mel 140 mg/m2. The primary ob-
jective was to determine the safety and feasibility of add-
ing a single, partially HLA-mismatched CB unit to
a conventional RIC transplantation to augment GVT
in patients with advanced hematologic malignancies.
Secondary objectives were to determine (1) the rate of
aGVHD and cGVHD, (2) the relative engraftment ki-
netics of PBPCs and CB when coinfused, and (3) DFS.
Eligible patients were those with myeloma, leukemia,
or lymphoma beyond CR1 who were candidates for
a RIC regimen. One CB unit was a 4/6 HLA-matched
patient with a minimum of 1.5 107 TNCs/kg and
an HLA-identical donor with a minimum of 6 106
CD341 cells/kg. The first 10 donors were required to
be siblings for safety, and eligibility was subsequently
expanded to 10/10 matched unrelated donors. A total
of 2 106 CD341 cells/kg were reserved in the event
of graft failure.
The results indicated that 9 patients were alive,
with 8 in CR at a median follow-up of 3.3 months
from transplantation (range, 0.6-10.3 months). There
were 13 deaths, including 6 because of relapse, 5 be-
cause of infection, 1 because of GVHD, and 1 because
of graft failure (for 2 deaths within 30 days of trans-
plantation from infection or graft failure). The data
for this novel approach to salvage transplantation are
encouraging. There is evidence of an immunologic
effect of the CB cells, with hyperacute GVHD occur-
ring shortly after CB infusion. Disease control was
favorable. A longer follow-up is needed to assess the
long-term efficacy of this approach, and follow-up
trials will investigate the infusion of subsets of CB
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